Nā huahana

Ua alakaʻi ʻia kēia noiʻi e noiʻi i ka hopena proliferative o nā peptides soy meaʻai ma nā cell stem adult (ASCs) i ka loaʻa ʻole o ka serum a me kā lākou hiki ke hana.Ua ʻike ʻia ka hoʻonui ʻia ʻana o nā pūnaewele mesenchymal stem (ADSCs) i loaʻa i ke kino a me ke kaula koko (CB-MSCs) i mālama ʻia me nā peptides soy ma luna o 3-(4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide a me Click-iT 5-ethynyl-2'-deoxyuridine kahe cytometry assay.Eia kekahi, alakaʻi nā peptides soy i ka phosphorylation stepwise o ka p44 / 42 MAPK (ERK), ka pahuhopu mammalian o rapamycin (mTOR), p70 S6 kinase, S6 ribosomal protein (S6RP) a me ka eukaryotic initiation factor 4E (eIF4E) i ADSCs.Eia kekahi, ua hōʻike ʻia ka loiloi quantitative o nā cytokines ua hoʻonui nui ʻia ka hana o ka hoʻololi ʻana i ka mea ulu-beta1 (TGF-β1), vascular endothelial growth factor a me interleukin-6 i ka pane ʻana i ka mālama ʻana me nā peptides soy i nā ADSC a me CB-MSC.Pēlā nō, ua kāohi ʻia ka phosphorylation soy peptide-induced o ke ala ERK / mTOR / S6RP / eIF4E i ka pane ʻana i ka pretreatment me PD98059, kahi mea hoʻopaneʻe ERK kikoʻī.Eia kekahi, ʻo ka inhibition o TGF-β1 ma o PD98059 pretreatment a me ka hoʻohaʻahaʻa ʻana i ka hoʻonui ʻana o ADSC i hōʻike ʻia ua hoʻoulu ʻo TGF-β1 i ka phosphorylation o mTOR / S6RP / eIF4E.ʻO ka hui pū ʻana, hōʻike nā hopena o kēia noiʻi ʻana he hana koʻikoʻi ka hana ʻana o TGF-β1 e hilinaʻi ana iā ERK i ka hoʻonui ʻana o ka peptide soy o ADSC ma lalo o nā kūlana serum-free. Kuleana © 2012 Elsevier Inc.